Oculgen
欧科健
Oculgen (欧科健) is a Shenzhen-based biotech company focused on ophthalmic drug development. In December 2025, it raised a $30 million Series B co-led by Qiming Venture Partners, with follow-on participation from existing shareholders LongRiver and BioTrack Capital . The company is built around OCUL101, a first-in-class bispecific antibody targeting VEGF and complement C5 for three major retinal diseases: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA) . As of late 2025, Oculgen was preparing to launch Phase II trials in both China and the US starting January 2026, and has additional multi-antibody pipeline candidates in preclinical stages expected to file IND applications in 2026 . The company was founded by Dr. Chen Jiongguang (陈烱光) .
AI-generated — may contain errors, please verify.
Coverage
Qiming View | Qiming Venture Partners' Kan Chen: Innovative Drug Primary Market Recovers, Bullish on Domestic FIC Innovative Drugs
Qiming Venture Partners will continue to stand by exceptional companies with a long-term mindset, helping them navigate cycles and expand globally.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 45, 2025
Following the milestones of Qiming Venture Partners' portfolio companies, together with you.
Qiming Venture Partners co-leads $30M Series B in Shenzhen Oculgen, first-in-class bispecific OCUL101 enters Phase II in China and US
Focused on R&D of innovative ophthalmic drugs
